The choice between them depends on whether a researcher prefers a single-compound approach or a combination protocol
Leveraging its deep expertise in formulation science, largescale manufacturing, and commercialization, the company supports broader patient access to incretinrelated therapies and enhances competition within the rapidly evolving cardiometabolic treatment landscape
The future of diabetes and obesity treatment is rapidly evolving
(incretin) ,
eligibility typically requires a BMI of 35 kg/m or above (or 30 kg/m or above in certain ethnic groups), though thresholds vary by ICB Bariatric surgery referral for eligible patients, typically those with a BMI of 40 kg/m or above, or 35 kg/m or above with significant obesity-related comorbidities, in line with NICE guideline CG189 Structured diabetes prevention programmes for those at risk of type 2 diabetes These pathways offer genuine, monitored, and legally sanctioned routes to improved metabolic health
Paleo vs keto: which diet actually fits your life